In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Licenses Early Stage Stent Drug to Prevent Thrombosis

Executive Summary

Medtronic has gained rights to ReVas, a drug development program based on novel targets of vascular inflammation, from Resverlogix, for use with drug-eluting stents to prevent thrombosis.
Advertisement

Related Content

TCT Highlights: Late Stent Thrombosis Controversy Continues
World Congress of Cardiology: DES Safety Dominates Discussions
Medtronic: Making Convergence Pay
Medtronic, Abbott Swap to Stay In Drug Stent Race

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel